The American Journal of Managed Care6h
Nivolumab Approved as Neoadjuvant, Adjuvant Therapy for NSCLC by FDA
The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...
Cancer Therapy Advisor7h
Opdivo Approved in Neoadjuvant and Adjuvant Setting for Resectable NSCLC
The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.
Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting
Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...
Medscape1d
Nivolumab NSCLC Approval Expanded to Perioperative Setting
The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with ...
Monthly Prescribing Reference1d
Neoadjuvant/Adjuvant Opdivo Approved for Resectable NSCLC
The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.
Targeted Oncology1d
FDA Approves Perioperative Nivolumab in Resectable NSCLC
The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...
Oncology Nurse Advisor1d
Tivozanib Has Efficacy in Advanced Renal Cell Carcinoma Post-ICI Therapy
No benefit seen for rechallenge with nivolumab after progression in the post-immune checkpoint inhibitor setting.
Labroots1d
Uncovering a Mechanism of Immunotherapy Response in Lung Cancer
When cancer cells mutate, they produce small peptides called neoantigens.  Because neoantigens remain relatively unique to ...
MedPage Today2d
De-Intensified Therapy Misses Mark in HPV-Positive Oropharyngeal Cancer
Two strategies to de-escalate treatment for human papillomavirus (HPV)-positive oropharyngeal cancer failed to show ...
Cure Today2d
Longer Time Until Recurrence Associated With Better Melanoma Outcomes
An expert explains study findings that associate a longer time until postsurgical melanoma recurrence with improved ...
Researchers build first large-scale atlas of how immune cells react to mutations during cancer immunotherapy
A Cleveland Clinic-led research collaboration between Timothy Chan, MD, Ph.D., Chair of Cleveland Clinic's Global Center for ...
Business Insider3d
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
The Phase 2b HBV003 trial (NCT05343481) has enrolled 121 participants and is designed to obtain critical dosing information for a potential functional cure regimen for CHB, with participants receiving ...